Reports
Sale
Chronic Obstructive Pulmonary Disease (COPD) Market Report: By Treatment Type: Drugs, Surgery, Oxygen Therapy, Others; By Disease Type: Emphysema, Chronic Bronchitis; By Route of Administration: Oral, Inhalation, Parenteral; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Model; Supplier Landscape; 2024-2032
Chronic Obstructive Pulmonary Disease (COPD) Market Outlook
The chronic obstructive pulmonary disease (COPD) market size was valued at USD 18.4 billion in 2023, driven by the increased tobacco consumption across the 7 major markets. The market is expected to grow at a CAGR of 5.3% during the forecast period of 2024-2032, with the values likely to rise from USD 19.4 billion in 2024 to USD 29.4 billion by 2032.
Chronic Obstructive Pulmonary Disease (COPD): Introduction
Chronic obstructive pulmonary disease (COPD) is a common lung disease in which a patient suffers from breathing issues because the airflow gets restricted. It is also known as emphysema or chronic bronchitis. There are chances that lungs may get clogged with phlegm in people suffering from it. The symptoms of chronic obstructive pulmonary disease include cough (with or without phlegm), breathing issues, wheezing, and exhaustion. The most common causes of chronic obstructive pulmonary disease include smoking and air pollution.
Chronic Obstructive Pulmonary Disease (COPD) Market Analysis
The increasing prevalence of chronic obstructive pulmonary disease within the 7 major markets is directly contributing to the chronic obstructive pulmonary disease market demand. The increase in COPD prevalence is due to several factors such as increasing aging population, increased urbanization, and other lifestyle habits. As people age, they are more susceptible to developing COPD due to decreased immunity rates with age. The increasing population of vehicles has been contributing to a rise in pollution levels in the urban cities and with the population density being high, it is directly contributing to the rise in COPD. Additionally, increased involvement of smoking and decreased health maintenance contributes to the rise in number of cases.
The chronic obstructive pulmonary disease market growth is driven by the advent of novel treatment alternatives for patients. In March 2023, Sanofi revealed that their potential COPD drug called Dupixent® showed favourable results in the Phase 3 trials. It is the first and only biologic to demonstrate a 30% reduction in acute as well as moderate exacerbations of COPD.
In addition to pharmacological treatments, surgical interventions like the lung volume reduction surgery, bullectomy and lung transplant are also being used on patients with severe conditions. With the prevalence of personalised treatments and targeted biologics, triple drug combinations that include the use of long-acting beta antagonists (LABAs), long-acting muscarinic antagonists (LAMA), and inhaled steroids are being considered as a valid treatment alternative. As research continues to progress, we can anticipate some significant treatment breakthroughs in the coming years, which will contribute significantly to the chronic obstructive pulmonary disease market share in the future.
Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation
Market Breakup by Treatment Type
- Drugs
- Bronchodilator Monotherapy
- Short-Acting Beta-2 Agonists
- Long-Acting Beta-2 Agonists
- Others
- Anti-Inflammatory Drugs
- Oral and Inhaled Corticosteroids
- Anti-Leukotrienes
- Others
- Bronchodilator Monotherapy
- Surgery
- Lung Volume Reduction Surgery
- Lung Transplant
- Bullectomy
- Others
- Oxygen Therapy
- Others
Market Breakup by Disease Type
- Emphysema
- Chronic Bronchitis
Market Breakup by Route of Administration
- Oral
- Inhalation
- Parenteral
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Chronic Obstructive Pulmonary Disease (COPD) Market Overview
The United States held a substantial portion of the chronic obstructive pulmonary disease market share during the historical period. Factors like a prominent healthcare ecosystem, coupled with core MedTech companies prevailing in the area contributed to the significant market growth. This trend is expected to continue, with the launch of several informative initiatives like the Learn More Breathe Better® Community Subcontract Program, which is organised by the National Heart, Lung, and Blood Institute (NHLBI). This program offers funding to organisations all over the country to offer better health education initiatives.
As a hub of medical inventions, Europe has been a key player in the COPD market. Having significant research and academic institutions along with a well-equipped infrastructure fosters major scope for the development of groundbreaking treatments.
The Asia Pacific region is home to various developing countries undergoing rapid urbanisation. As a result, the population living in the region is more susceptible to developing COPD due to higher exposure to pollution levels. Moreover, countries like Japan and China have a massive size of geriatric population, leaving the countries at an increased risk of facing more COPD cases. Identifying the current trend, the region is experiencing essential infrastructure developments in hospitals and research labs to combat the high chronic obstructive pulmonary disease market demand that may arise in the future.
Chronic Obstructive Pulmonary Disease (COPD) Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- GlaxoSmithKline plc (GSK)
- AstraZeneca
- Boehringer Ingelheim
- Novartis
- Teva Pharmaceutical Industries
- Viatris (formerly Mylan)
- Sunovion Pharmaceuticals
- Cipla
- Merck & Co., Inc.
- Vectura Group
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Circassia Pharmaceuticals
- Theravance Biopharma
- Almirall
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Chronic Obstructive Pulmonary Disease (COPD) Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
5.3.1 Germany Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
5.3.2 France Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
5.3.3 Italy Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
5.3.4 Spain Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
5.4 Japan Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2017-2032)
6 Chronic Obstructive Pulmonary Disease (COPD) Market Overview – 7MM
6.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2017-2023)
6.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2024-2032)
7 Chronic Obstructive Pulmonary Disease (COPD) Market Landscape – 7MM
7.1 Chronic Obstructive Pulmonary Disease (COPD)Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Chronic Obstructive Pulmonary Disease (COPD)Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Route of Administration
8 Chronic Obstructive Pulmonary Disease (COPD)Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation – 7MM
11.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
11.1.1 Market Overview
11.1.2 Drugs
11.1.2.1 Bronchodilator Monotherapy
11.1.2.1.1 Short-Acting Beta-2 Agonists
11.1.2.1.2 Long-Acting Beta-2 Agonists
11.1.2.1.3 Others
11.1.2.2 Anti-Inflammatory Drugs
11.1.2.2.1 Oral and Inhaled Corticosteroids
11.1.2.2.2 Anti-Leukotrienes
11.1.2.2.3 Others
11.1.3 Surgery
11.1.3.1 Lung Volume Reduction Surgery
11.1.3.2 Lung Transplant
11.1.3.3 Bullectomy
11.1.3.4 Others
11.1.4 Oxygen Therapy
11.1.5 Others
11.1.6 Chronic Obstructive Pulmonary Disease (COPD) Market by Disease Type
11.1.6.1 Market Overview
11.1.6.2 Emphysema
11.1.6.3 Chronic Bronchitis
11.1.7 Chronic Obstructive Pulmonary Disease (COPD) Market by Route of Administration
11.1.7.1 Market Overview
11.1.7.2 Oral
11.1.7.3 Inhalation
11.1.7.4 Parenteral
11.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Region
11.2.1 Market Overview
11.2.2 United States
11.2.3 EU-4 and the United Kingdom
11.2.3.1 Germany
11.2.3.2 France
11.2.3.3 Italy
11.2.3.4 Spain
11.2.3.5 United Kingdom
11.2.4 Japan
12 United States Chronic Obstructive Pulmonary Disease (COPD)Market
12.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2017-2023)
12.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2024-2032)
12.3 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
12.4 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
13 EU-4 and United Kingdom Chronic Obstructive Pulmonary Disease (COPD)Market
13.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2017-2023)
13.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2024-2032)
13.3 Germany Chronic Obstructive Pulmonary Disease (COPD) Market Overview
13.3.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
13.3.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
13.4 France Chronic Obstructive Pulmonary Disease (COPD) Market Overview
13.4.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
13.4.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
13.5 Italy Chronic Obstructive Pulmonary Disease (COPD) Market Overview
13.5.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
13.5.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
13.6 Spain Chronic Obstructive Pulmonary Disease (COPD) Market Overview
13.6.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
13.6.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
13.7 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Market Overview
13.7.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
13.7.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
14 Japan Chronic Obstructive Pulmonary Disease (COPD)Market
14.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2017-2023)
14.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2024-2032)
14.3 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
14.4 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 GlaxoSmithKline plc (GSK)
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 AstraZeneca
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Boehringer Ingelheim
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Novartis
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Teva Pharmaceutical Industries
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Viatris (formerly Mylan)
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Sunovion Pharmaceuticals
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Cipla
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Merck & Co., Inc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Vectura Group
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Pfizer Inc.
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Regeneron Pharmaceuticals
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Circassia Pharmaceuticals
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Theravance Biopharma
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Almirall
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Chronic Obstructive Pulmonary Disease (COPD)Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 18.4 billion in 2023, driven by the rising prevalence of tobacco indulgence across the globe.
The market is anticipated to grow at a CAGR of 5.3% during the forecast period of 2024-2032, likely to reach a market value of USD 29.4 billion by 2032.
The increased involvement in tobacco consumption, along with prolonged exposure to higher pollution levels, is contributing to the high market demand.
The pharmaceutical companies are continuously developing new medications and equipment to improve the efficacy of chronic obstructive pulmonary disease treatment, which is a key trend in the market. In March 2023, Sanofi revealed that Dupixent®, their potential COPD drug showed favourable results in the Phase 3 trials.
The treatment types include drugs, surgery, and oxygen therapy, among others.
The disease types include emphysema and chronic bronchitis.
The routes of administration in the market are oral, inhalation, and parenteral.
The major regions of the market include the United States, Japan, EU-4, and the United Kingdom.
Key players involved in the market are GlaxoSmithKline plc (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceutical Industries, Viatris (formerly Mylan), Sunovion Pharmaceuticals, Cipla, Merck & Co., Inc., Vectura Group, Pfizer Inc., Regeneron Pharmaceuticals, Circassia Pharmaceuticals, Theravance Biopharma, and Almirall.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER